Paclitaxel belongs to the group of medications known as antineoplastics and is used in the treatment of cancers. It works by inhibiting the growth of cancer cells and is used in the treatment of various cancers such as breast cancer, ovarian cancer, non small cell lung cancer, etc. According to the WHO, cancer was the leading cause of death worldwide, accounting for the death of 8.2 million people in 2012. The major drivers for this market are the rising incidence of cancer globally and the improved efficacy of paclitaxel injections. However, adverse drug reactions associated with the drug as well as the emergence of targeted treatment, personalized medicine and novel anti-cancer drugs would be a challenge to the growth of this market. The opportunities for this market are its potential to be used for treatment for various types of cancers.
Paclitaxel Injection Market by use in treatment of various cancers
Paclitaxel Injection is used in the treatment of Breast cancer, Ovarian cancer, Non small cell lung cancer, AIDS related Kaposi's sarcoma, Cervical Cancer, Esophageal cancer, Prostate cancer , Stomach cancer, Testicular cancer, Lung cancer, Pancreatic cancer, and Others. According to the WHO, stomach cancer accounted for 723,000 deaths and breast cancer accounted for 521,000 deaths respectively in the year 2012 alone. Paclitaxel is used for the treatment of both these cancers and the rising incidences of cancer would result in increased use of this drug for treatment.
Paclitaxel Injection Market by Geography
Paclitaxel Injection Market is segmented geographically into North America, Europe, Asia Pacific and RoW. Currently the market is dominated by North America due to the high incidence of Cancer patients in this region. However, Europe and Asia Pacific are emerging markets due to rising incidences of cancer.
Competitive analysis
The companies in this market are Abraxis Bio Science Inc., Celgene, Abbott Laboratories, Fresenius Kabi Oncology Ltd, Onco therapies Ltd, Novasep, Sagent Pharmaceuticals and others. The European Commission approved ABRAXANE to be taken in combination with Gentamicin for the treatment of metastatic pancreatic cancer in January 2014. ABRAXANE was developed by Celgene International Sàrl, a subsidiary of Celgene Corporation.
High Level Analysis
Porter’s five force model analyzes the bargaining power of the suppliers and buyers as well as the threat of new entrants. The threat of substitutes in this market is high, with extensive research and development being carried out in anti-cancer drugs. SWOT analysis helps in making strategic decisions for development and expansion. The key drivers, restraints and opportunities are analyzed to help in better understanding the growth of this market.
Key Benefits
- Market segmentation by use of the product would help in identification of future applications
- Porter’s five force model helps in making strategic business decisions for business development
- In-depth geographic Analysis would aid in identifying regions where demand for this product would increase
- In-depth analysis of drivers and opportunities would help in understanding the future potential of this market
Paclitaxel Injection Market Report Highlights
| Aspects | Details |
 By use in treatment of various cancers |
|
 By Geography |
|
 Key Market Players | Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Accord Healthcare Inc., Merck & Co Inc., Pfizer Inc., Novartis AG, Natco Pharma Ltd., Hetero Drugs Ltd. |
Loading Table Of Content...
